01 June 2005 : Original article
HESA-A: new treatment for breast cancer and choroidal metastasis
Amrollah Ahmadi, Mohammad Ali Mohagheghi, Mohammad Sadegh Fazeli, Bijan Nahavandian, Nasrollah Bashardoost, Alireza Musavi Jarahi, Marjan GharipoorMed Sci Monit 2005; 11(6): CR300-303 :: ID: 16509
Abstract
Summary
Background: Breast cancer is one of the main causes of mortality among women worldwide. This type of cancer metastasizes to different body tissues, giving rise to many problems. The effect of HESA-A, a drug of herbal-marine origin, on vision, quality of life, and survival of end-stage breast cancer patients was investigated in this study.
Material/Methods: In a double-blind study, 24 breast cancer patients with choroidal metastasis, aged between 41 and 49 years, were divided into case and control groups, treated with 50 mg/kg/day of HESA-A and placebo, respectively. The patients were evaluated in respect to the intensity of experienced pain, by assessing their rate of narcotic analgesic use. The patients’ vision scale was also evaluated.
Results: Notable improvement was seen in the vision of patients treated with HESA-A. Patients receiving HESA-A used narcotics at lower doses, owing to reduced experience of pain. No changes were observed
in the vision of control group patients, or their pain experience.
Conclusions: The effects of natural compounds with antioxidant and anticancer properties have been emphasized by different studies. HESA-A is a compound of natural origin, consisting of rare elements and organic materials, which in several animal and cellular studies has shown powerful anticancer effects and less toxicity on normal cells. The results of this study showed considerable improvement
in the vision of breast cancer patients treated with HESA-A.
Keywords: Choroid Neoplasms - drug therapy, Choroid Neoplasms - mortality, Choroid Neoplasms - pathology, Choroid Neoplasms - physiopathology, Choroid Neoplasms - secondary, Bone Neoplasms - secondary, Breast Neoplasms - pathology, Choroid Neoplasms - secondary, Double-Blind Method, Pain - prevention & control, Patient Selection, Phytotherapy, Plant Preparations - therapeutic use, Survival Analysis, Vision Disorders - etiology, Vision, Ocular - physiology
732 3
Editorial
01 May 2023 : Editorial
Editorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor TherapyDOI: 10.12659/MSM.940911
Med Sci Monit 2023; 29:e940911
In Press
28 May 2023 : Database Analysis
Scientometric and Visualized Analysis of Intravoxel Incoherent Motion Magnetic Resonance Imaging: 1988-2021Med Sci Monit In Press; DOI: 10.12659/MSM.938715
25 May 2023 : Database Analysis
The COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in PolandMed Sci Monit In Press; DOI: 10.12659/MSM.940904
25 May 2023 : Review article
A Review of Preclinical and Clinical Studies in Support of the Role of Non-Steroidal Anti-Inflammatory Drug...Med Sci Monit In Press; DOI: 10.12659/MSM.940635
25 May 2023 : Clinical Research
Periapical Lesions and Missed Canals in Endodontically Treated Teeth: A Cone-Beam Computed Tomographic Stud...Med Sci Monit In Press; DOI: 10.12659/MSM.940533
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952